Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Lixisenatide in patients with type 2 diabetes and Acute Coronary Syndrome
If youre unsure about any step or experience unexpected side effects, consult your healthcare provider right away
doi: 10.1186/s12891-022-05396-5 Summary Keywords type 2 diabetes, osteoporosis, GLP-1 receptor agonists, electronic medical records, cohort study, bone metabolism, fracture risk Citation Chen M, Lyu Y, Zhao J, Han X, Huang T, Yang T and Zhou Y (2025) Use of GLP-1 receptor agonist and risk of osteoporosis among patients with type 2 diabetes: a real-world study
Sn phm hin c mt ti M Phm Ph Th , cc bn hy nhanh tay t mua ngay hm nay c th s hu mc gi u i cng nhiu nhng phn qu v cng hp dn nh
However, discontinuation rates were higher in the orforglipron groups
Semaglutides CV event reduction indication already comes from the SELECT trial which supported its FDA approval and payor reimbursement Prior to its cardiovascular approval in March 2024, semaglutide was already approved for diabetes (Ozempic) and weight loss (Wegovy)
US$ 25.47
US$ 25.66
US$ 20.59
US$ 28.99
US$ 28.25
US$ 29.15
